The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma

• Published in: Human genomics 2016-12, Vol.10 (1), p.40-40, Article 40
• Main Authors: Chang, Kuang-Leei, Lee, Ming-Yung, Chao, Wan-Ru, Han, Chih-Ping
• Format: Article
• Language: English
• Subjects: Letter to the Editor
• ISSN: 1479-7364; 1473-9542; 1479-7364
• DOI: 10.1186/s40246-016-0096-9

Jayson GC et al. remarked in Lancet that nearly 100% of mucinous ovarian cancer cases have Kras mutation as well as a high frequency of Her2 amplification. Using the Abbott PathVysion Her2 DNA Probe Kit and Kras mutant-enriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenocarcinomas from Taiwanese patients were examined to determine the status of Her2 amplification and Kras mutations. Our results showed the Her2 amplification rates were 33.33%, while the Kras mutation rates were 61.90%. We present here our results in order to enlighten the readership that the ~100% Kras mutant frequency and the high Her2 amplification rate reported by Jayson et al. may be too exaggerated to be applicable into all populations. Additionally, we report another 2 novel Kras mutations (A11V, V14I).